Trial Update November 12, 2026

Tesamorelin Phase 2 Trial for Liver Fat Reduction Now Recruiting

A clinical trial update dated November 12, 2026 reports new status for a study involving tesamorelin. The trial, titled "Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease," is registered as NCT07481734. It is listed as a Phase 2 study. According to the update, the trial status is currently recruiting. The study focuses on adults with fatty liver disease and examines tesamorelin in relation to liver fat reduction, as stated in the trial title. No results have been posted as part of this update, and no outcome data are available at this time. This entry reflects only the recruitment status and trial design information provided in the registry listing. Readers interested in the study can review the full registration details through the official clinicaltrials.gov listing for additional information on eligibility and trial design. Tesamorelin remains classified for research use under current regulatory status noted alongside this update. For broader context on tesamorelin as a compound, readers can consult the compound overview.

See the full sermorelin overview

Source: https://clinicaltrials.gov/study/NCT07481734